Thought disorders among non-demented outpatients with Parkinson's disease: Prevalence and associated factors

Journal of Neural Transmission

Volumn 117, Issue 10, 2010, Pages 1183-1188

  Debs, Rachel ^a   Cochen De Cock, Valérie ^a,c   Nègre Pagès, Laurence ^a,b   Aristin, Marina ^b   Senard, Anna ^a   Rascol, Olivier ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b LN Pharma   (France)

^c CHU PURPAN   (France)

Author keywords

Depression; Dysautonomia; Hallucinations; Parkinson's disease; Sleep disorders; Thought disorders

Indexed keywords

AGED; ANXIETY DISORDER; ARTICLE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DELUSION; DEPENDENT PERSONALITY DISORDER; DEPRESSION; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DYSAUTONOMIA; FEMALE; HALLUCINATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; PARAMETRIC TEST; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; SLEEP DISORDER; THOUGHT DISORDER; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VIVID DREAM;

AGED; AGED, 80 AND OVER; COGNITION DISORDERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE; RISK FACTORS;

EID: 78651229771     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0458-8     Document Type: Article

References (31)

1. D Aarsland JP Larsen JL Cummins, et al. 1999 Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study Arch Neurol 56 595 601 1:STN:280:DyaK1M3lvVyjtQ%3D%3D 10.1001/archneur.56.5.595 10328255 (Pubitemid 29218155)
2. CH Adler KD Sethi RA Hauser, et al. 1997 Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group Neurology 49 393 399 1:CAS:528:DyaK2sXmtVGisbw%3D 9270567
3. I Arnulf AM Bonnet P Damier, et al. 2000 Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis Neurology 55 281 288 1:STN:280:DC%2BD3czpvVartg%3D%3D 10908906
4. J Barnes AS David 2001 Visual hallucinations in Parkinson's disease: a review and phenomenological survey J Neurol Neurosurg Psychiatry 70 727 733 1:STN:280:DC%2BD3MzhtF2qtg%3D%3D 10.1136/jnnp.70.6.727 11385004 (Pubitemid 32554201)
5. DJ Buysse CF Reynolds 3rd TH Monk, et al. 1989 The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research Psychiatry Res 28 193 213 1:STN:280:DyaL1Mzhs1Wmsg%3D%3D 10.1016/0165-1781(89)90047-4 2748771 (Pubitemid 19144991)
6. CL Comella CM Tanner RK Ristanovic 1993 Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations Ann Neurol 34 710 714 1:STN:280:DyaK2c%2FlvVWnsA%3D%3D 10.1002/ana.410340514 8239565 (Pubitemid 23333244)
7. G Fenelon F Mahieux R Huon, et al. 2000 Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors Brain 123 733 745 10.1093/brain/123.4.733 10734005
8. HH Fernandez D Aarsland G Fenelon JH Friedman L Marsh AI Troster, et al. 2008 Scales to assess psychosis in Parkinson's disease: critique and recommendations Mov Disord 23 484 500 10.1002/mds.21875 18175343
9. CG Goetz GT Stebbins 1993 Risk factors for nursing home placement in advanced Parkinson's disease Neurology 43 2227 2229 1:STN:280: DyaK2c%2FltVKjug%3D%3D 8232934
10. CG Goetz GT Stebbins 1995 Mortality and hallucinations in nursing home patients with advanced Parkinson's disease Neurology 45 669 671 1:STN:280:DyaK2M3ktVynug%3D%3D 7723953
11. CG Goetz J Wuu LM Curgian S Leurgans 2005 Hallucinations and sleep disorders in PD: six-year prospective longitudinal study Neurology 64 81 86 15642908
12. S Holroyd L Currie GF Wooten 2001 Prospective study of hallucinations and delusions in Parkinson's disease J Neurol Neurosurg Psychiatr 70 734 738 1:STN:280:DC%2BD3MzhtF2qtw%3D%3D 10.1136/jnnp.70.6.734 11385005 (Pubitemid 32554202)
13. Hosmer DW, Lemshow S (1989) Applied logistic regression. Wiley, Toronto
14. International Association for the Study of Pain, Subcommittee on Taxonomy (1986) Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain Suppl 3:S1-S226
15. C Jenkinson R Fitzpatrick V Peto, et al. 1997 The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score Age Ageing 26 353 357 1:STN:280:DyaK1c%2FhtFyntg%3D%3D 10.1093/ageing/26.5.353 9351479 (Pubitemid 27448379)
16. PA Kempster DR Williams M Selikhova, et al. 2007 Patterns of levodopa response in Parkinson's disease: a clinico-pathological study Brain 130 2123 2128 1:STN:280:DC%2BD2svksFCgsA%3D%3D 10.1093/brain/awm142 17586867 (Pubitemid 47236624)
17. J Marinus AF Leentjens M Visser, et al. 2002 Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease Clin Neuropharmacol 25 318 324 10.1097/00002826-200211000-00008 12469006 (Pubitemid 36025272)
18. L Negre-Pages W Regragui D Bouhassira, et al. 2008 Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey Mov Disord 23 1361 1369 10.1002/mds.22142 18546344
19. T Nomura Y Inoue H Mitani, et al. 2003 Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease Mov Disord 18 812 817 10.1002/mds.10439 12815661 (Pubitemid 36939977)
20. H Oka M Yoshioka K Onouchi, et al. 2007 Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations Mov Disord 22 1510 1514 10.1002/mds.21581 17516497 (Pubitemid 47280645)
21. C Pacchetti R Manni R Zangaglia, et al. 2005 Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease Mov Disord 20 1439 1448 10.1002/mds.20582 16028215 (Pubitemid 43072652)
22. EJ Pappert CG Goetz FG Niederman, et al. 1999 Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease Mov Disord 14 117 121 1:STN:280:DyaK1M7hsV2isA%3D%3D 10.1002/1531-8257(199901)14:1<117:: AID-MDS1019>3.0.CO;2-0 9918353 (Pubitemid 29224685)
23. RB Postuma JF Gagnon J Montplaisir 2008 Autonomic dysfunction in RBD-what can it teach us about disease progression? Sleep Med 9 473 474 10.1016/j.sleep.2007.10.002 18024175 (Pubitemid 351837482)
24. O Rascol B Dubois AC Caldas, et al. 2006 Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study Mov Disord 21 2110 2115 10.1002/mds.21122 17013922 (Pubitemid 46140421)
25. JR Sanchez-Ramos R Ortoll GW Paulson 1996 Visual hallucinations associated with Parkinson disease Arch Neurol 53 1265 1268 1:STN:280: DyaK2s7isFektg%3D%3D 8970453
26. Schwab R, England A (1969) Projection techniques for evaluating surgery in Parkinson's disease. In: Edinburgh RCoSi (ed) Third symposium on Parkinson's disease. E. & S. Livingstone Ltd, pp 152-157
27. RS Schwab AC England Jr DC Poskanzer, et al. 1969 Amantadine in the treatment of Parkinson's disease JAMA 208 1168 1170 1:STN:280: DyaF1M7nvFCltA%3D%3D 10.1001/jama.208.7.1168 5818715
28. M Selikhova DR Williams PA Kempster JL Holton T Revesz AJ Lees 2009 A clinico-pathological study of subtypes in Parkinson's disease Brain 132 2947 2957 1:STN:280:DC%2BD1MjhvV2gtg%3D%3D 10.1093/brain/awp234 19759203
29. KM Shannon JP Bennett Jr JH Friedman 1997 Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group Neurology 49 724 728 1:CAS:528:DyaK2sXmtlOmtbs%3D 9305331
30. EY Uc MP McDermott KS Marder SW Anderson I Litvan PG Como, et al. 2009 Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort Neurology 73 1469 1477 1:STN:280: DC%2BD1MjjsFOhsQ%3D%3D 10.1212/WNL.0b013e3181bf992f 19884574
31. CH Williams-Gray T Foltynie CE Brayne, et al. 2007 Evolution of cognitive dysfunction in an incident Parkinson's disease cohort Brain 13 1787 1798 10.1093/brain/awm111 (Pubitemid 47343805)